Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of human therapeutics using antisense technology. This proprietary platform ena... Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of human therapeutics using antisense technology. This proprietary platform enables the creation of novel drugs targeting difficult-to-treat diseases across cardiovascular, metabolic, neurological, and rare disease areas. Key marketed products include TRYNGOLZA (olezarsen), the first FDA-approved treatment for adults with familial chylomicronemia syndrome as an adjunct to diet; DAWNZERA (donidalorsen), an RNA-targeted prophylactic therapy for hereditary angioedema in patients 12 years and older; and royalties from partnered drugs such as SPINRAZA (nusinersen) for spinal muscular atrophy, WAINUA (eplontersen) for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Qalsody for ALS, Tegsedi, and Waylivra. Ionis maintains a broad pipeline of investigational medicines, including olezarsen for severely elevated triglycerides, zilganersen for Alexander disease, bepirovirsen for chronic hepatitis B, ulefnersen for FUS-ALS, sapablursen for polycythemia vera, and opemalirsen for APOL1-mediated kidney disease. The company generates revenues from product sales, royalties, and R&D collaborations with partners like Biogen and AstraZeneca. Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a pivotal role in advancing RNA-targeted therapies for unmet medical needs.
No Climate Targets data disclosed by Ionis Pharmaceuticals
We reviewed Ionis Pharmaceuticals's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.
If you would like us to review newly published materials or reassess the most recent
disclosures, you can submit a data update request.
Account Restricted
Your account has been restricted and you no longer have access to paid features.
Contact our support team
or
upgrade your plan
to unblock your account.